- Home
- IMRX vs PRQR Comparison
IMRX vs PRQR Comparison
Compare IMRX & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMRX | PRQR |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.8M | 262.5M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IMRX | PRQR |
|---|---|---|
| Price | $4.17 | $1.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $17.20 | $7.25 |
| AVG Volume (30 Days) | ★ 646.0K | 571.9K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.86 | $1.33 |
| 52 Week High | $8.48 | $3.10 |
Technical Indicators
Market Signals| Indicator | IMRX | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 36.28 | 30.55 |
| Support Level | $3.98 | $1.37 |
| Resistance Level | $5.32 | $1.99 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 3.28 | 0.81 |
Price Performance
Historical ComparisonAbout IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.